The major factor contributing to morbidity and mortality in cystic fibrosis is progressive pulmonary disease.' 2 The dominant pathogen in older patients is now Pseudomonas aeruginosa, and no antibiotic regimen has yet achieved more than a transient eradication or suppression of this organism in cystic fibrosis patients' sputum.3 Within a given group of patients with cystic fibrosis, those without pseudomonas infection are in better general condition than those harbouring the organism; and there is an association between pseudomonas infection and the severity of pulmonary disease.' 4 In a recent longitudinal study pseudomonas infection was the only factor significantly associated with a deterioration in the condition of an individual patient with time.5 For these reasons cystic fibrosis patients colonised by pseudomonas who experience an acute exacerbation of their respiratory symptoms are treated with courses of antibiotics directed against pseudomonas, despite the lack of good scientific evidence that specific antipseudomonal chemotherapy is beneficial.3
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Azlocillin is a semisynthetic acylureido penicillin with a high in vitro activity against pseudomonas. It has a lower sodium content than some other semisynthetic penicillins, which may be an advantage in patients with cor pulmonale. In this study azlocillin and gentamicin were compared with carbenicillin and gentamicin in patients with cystic fibrosis infected with P aeruginosa.
Methods

PATIENTS AND TREATMENT
Twenty adults with a proved diagnosis of cystic fibrosis admitted to hospital consecutively with acute exacerbations of respiratory symptoms, increasing volumes of purulent sputum, and deterioration in lung function were studied. Peak expiratory flow rate (PEFR), FEV,, and forced vital capacity (FVC) were measured on admission and patients were included if these showed a fall of at least 20% below outpatient values. Patients with severe disease, defined as FEV, of <20% of predicted normal values,6 were excluded. All patients had had persistent P aeruginosa in their sputum for at least six months before the study. Patients with a history of penicillin allergy, appreciable liver disease, or cor pulmonale and those with organisms resistant to 299 300 azlocillin or carbenicillin were excluded. In a single blind study, patients were randomly allocated to carbenicillin or azlocillin groups, and all patients received gentamicin intravenously eight hourly, the dose being adjusted to give a serum concentration of 8-10 ug/ml 15 minutes after a bolus injection. The dose of azlocillin was 5 g eight hourly and of carbenicillin 5 g six hourly. Both were given by slow intravenous infusion over 20 minutes, and all treatments were given for an arbitrary period of 10 days.
All patients received physiotherapy with postural drainage four times daily. Those with a proved reversible element of airflow obstruction received bronchodilators. Patients with other pathogens in the initial sputum culture received appropriate oral chemotherapy.
CLINICAL ASSESSMENT
Patients were assessed and examined on the first and last day of treatment by the same physician. PEFR was recorded on a Wright peak flow meter, and FEV, and FVC were recorded on a Vitalograph spirometer. A subjective assessment of patients' wellbeing was scored on a 10 cm visual analogue scale. Patients were asked to mark their present position on the scale by comparison with the worst that they had ever felt (0) and the best that they had felt in the previous 12 months (10). Full blood counts and erythrocyte sedimentation rates were determined and liver function tests and urea and electrolyte measurements performed to monitor toxicity. Serum samples Serum azlocillin and carbenicillin assays were performed by bioassay after pretreatment of the serum with a resin to remove any gentamicin present. One millilitre of serum was added to 100 mg of Dowex 50-X8 resin (British Drug Houses) and mixed on a rotator for 15 minutes. The resin was allowed to settle by letting it stand for a further five minutes and the supernatant serum was removed. The bioassays for azlocillin and for carbenicillin were performed on DST agar (Oxoid) with P aeruginosa (National Collection of Type Cultures 10701) as the indicator organism. Standards of 2-5-40 ug/ml were prepared for both antibiotics in horse serum (No 3 Wellcome) and resin absorbed test sera were appropriately diluted in serum in order to bring them within the concentrations of the standard curve range. After incubation for 18 hours at 37°C, inhibition zone diameters were measured with a zone projector (Leebrook Instruments). Derandomisation and calculation of the results were performed according to the method of Perkins.9
MICROBIOLOGY
Sputum samples Sputum was homogenised by vigorous agitation on a vortex mixer in a bottle containing six 5 5 mm glass beads. The homogenates were then treated in the same way as serum samples.
STATISTICS
Baseline data on the two groups of patients on entry to the study were compared with Wilcoxon's rank sum test. The improvements in respiratory function with the two treatments were compared with an analysis of covariance.
Results
RESPIRATORY FUNCTION
There was no significant difference between the two groups of patients on entry to the trial ( The MIC ranges of azlocillin and carbenicillin for P aeruginosa from 12 patients with cystic fibrosis were similar to those reported for strains of pseudomonas from other patients with infections,'8 and lower than the MIC50 values quoted by Prince and Neu for 62 isolates from patients with cystic fibrosis.'9 The rise in the MIC of carbenicillin seen in three strains suggests the development of antibiotic resistance during the course of treatment, while the presence of different strains after treatment in two patients may be due to selective reduction of a previously dominant strain by the treatment. The therapeutic ratio of peak serum concentrations of azlocillin (628.6 A.g/ml) to the highest MIC of azlocillin (12.5 Ag/ml) was 503, the equivalent ratio for carbenicillin being 308-9/200-that is, 1-6. Azlocillin might therefore be expected to have far greater clinical efficacy in patients with pseudomonas bacteraemia. The therapeutic ratios in sputum, however, were very much lower-0-26 for azlocillin and 0-05 for carbenicillin. Not The present study was designed as a randomised comparative trial, excluding severely ill patients. We have measured a clinical response, primarily in terms of respiratory function tests, and also included an assessment of patients' well being. As expected, there was no change in the bacteriological characteristics of the sputum. We have documented a significant and substantial improvement in respiratory function in patients with cystic fibrosis treated acutely with antipseudomonal antibiotics. Despite the difference in in vitro activity against pseudomonas of the two penicillins we compared, there was no difference in the degree of response. Neither penicillin penetrated sputum well, but azlocillin has the practical advantages of a low sodium content and a recommended eight hour dose interval. Before the advent of antipseudomonal antibiotics patients with cystic fibrosis were admitted to hospital for physiotherapy, with moderate improvement in respiratory function. The response to antibiotics was considered to be much greateralthough, regrettably, this was not documented in any formal way. At the time many clinicians thought that placebo controls might be unethical. Perhaps the time has now come for a placebo controlled trial to assess how much of the observed benefit of treatment is due to hospital care and physiotherapy alone.
